News

M24S includes the minimal inhibitory concentrations and QC ranges developed following the standards described in CLSI document M24, which includes susceptibility testing procedures for Mycobacterium tuberculosis complex (MTBC), clinically significant slowly and rapidly growing mycobacterial species, Nocardia spp., and other aerobic actinomycetes.

Malvern, Pennsylvania, USA—The Clinical and Laboratory Standards Institute (CLSI) has published CLSI EP12—Evaluation of Qualitative, Binary Output Examination Performance, 3rd Ed.

CLSI has published M100—Performance Standards for Antimicrobial Susceptibility Testing, 33rd Edition. The tables presented in M100 represent the most current information for drug selection, interpretation, and quality control using the procedures standardized in CLSI documents M02, M07, and M11. This document is intended for use by microbiology labs, antimicrobial stewardship teams, infectious disease experts, and other relevant stakeholders intending to provide optimal patent care using the most up-to-date antimicrobial susceptibility breakpoints and test methods. To ensure the correct use of the document, users should replace previously published tables with the new edition immediately.

The Clinical and Laboratory Standards Institute announces the recipients of its 2023 Excellence Awards. These awards celebrate the achievements of CLSI volunteers and organizational members who are committed to CLSI’s mission and have helped improve the quality of medical care worldwide. Recipients are recognized for dedicating significant time and effort to the development, implementation, and promotion of CLSI standards.

The Clinical and Laboratory Standards Institute (CLSI) has published the 3rd Edition of EP19—A Framework for Using CLSI Documents to Evaluate Medical Laboratory Test Methods. The 3rd Edition of the EP19 Report is available free, and introduces the Test Life Phases Model, which points users to CLSI evaluation protocol documents to establish and implement commercially manufactured or laboratory-developed test (LDT) methods.

CLSI has announced that a new and updated version of the I/LA37 Database, Supplemental Data for Allergen Specificity for IgE Antibody Autoanalyzers, is now available. The updated database provides essential allergen information for allergy testing manufacturers and hospitals performing allergy testing, both laboratories and clinicians.

The Clinical and Laboratory Standards Institute (CLSI) announces that the Pan American Health Organization (PAHO) Member States have admitted CLSI into official relations as a non-state actor with PAHO for a period of three years (2022-2024). PAHO acts as the Regional Office for the Americas of the World Health Organization (WHO).

Romney M. Humphries, Vanderbilt University Medical Center, Nashville, TN The College of American Pathologists (CAP) is introducing two new requirements for clinical laboratories to use updated...